AKTS Aktis Oncology, Inc. - Common stock
$18,80
Harga · Mei 20, 2026
Fundamental per Mei 11, 2026
Rentang 52M
$15–$29
28% of range
Peringkat Analis
BUY
12 analysts
Target Harga
$32
+72% upside
P/E (TTM)
—
ROE
—
Margin Laba Bersih
—
AKTS Cuplikan Saham Harga, kapitalisasi pasar, P/E, EPS, ROE, utang/ekuitas, kisaran 52 minggu
Harga
$18.80
Kapitalisasi Pasar
—
P/E (TTM)
—
EPS (TTM)
—
Pendapatan (TTM)
—
Imbal Hasil Dividen
—
ROE
—
D/E Utang/Ekuitas
—
Rentang 52M
$15 – $29
AKTS Grafik Harga Saham OHLCV harian dengan indikator teknis — geser, perbesar, dan sesuaikan tampilan Anda
Configure
Kinerja 10 Tahun Tren Pendapatan, laba bersih, margin, dan EPS
Pendapatan & Laba Bersih
—
EPS
—
Arus Kas Bebas
—
Margin
—
Valuasi Rasio P/E, P/S, P/B, EV/EBITDA — apakah sahamnya mahal atau murah?
Metrik
Tren 5 Tahun
AKTS
Median Rekan
Profitabilitas Margin kotor, operasional, dan bersih; ROE, ROA, ROIC
Metrik
Tren 5 Tahun
AKTS
Median Rekan
Kesehatan Keuangan Utang, likuiditas, solvabilitas — kekuatan neraca
Metrik
Tren 5 Tahun
AKTS
Median Rekan
Pertumbuhan Pertumbuhan Pendapatan, EPS, dan Laba Bersih: YoY, CAGR 3T, CAGR 5T
Metrik
Tren 5 Tahun
AKTS
Median Rekan
Efisiensi Modal Perputaran aset, perputaran persediaan, perputaran piutang
Metrik
Tren 5 Tahun
AKTS
Median Rekan
AKTS Konsensus Analis Opini analis bullish dan bearish, target harga 12 bulan, potensi kenaikan
BELI
12 analis
- Beli Kuat 5 41,7%
- Beli 6 50,0%
- Tahan 1 8,3%
- Jual 0 0,0%
- Jual Kuat 0 0,0%
Target Harga 12 Bulan
5 analis · 2026-05-18
Median
$33.00
Rata-rata
$32.40
← Di bawah semua target
$18.80
Rendah
$30.00
Tinggi
$34.00
Target median
$33.00
+75,5%
Target rata-rata
$32.40
+72,3%
Riwayat Pendapatan EPS aktual vs perkiraan, kejutan %, tingkat keberhasilan, tanggal pendapatan berikutnya
Kejutan Rata-rata
-0.04%
| Periode | EPS Aktual | EPS Estimasi | Kejutan |
|---|---|---|---|
| 31 Maret 2026 | $-0.38 | $-0.34 | -0.04% |
Perbandingan Sejawat Metrik utama vs rekan sektor
| Ticker | Kapitalisasi Pasar | P/E | Pendapatan YoY | Margin Bersih | ROE | Margin Kotor |
|---|---|---|---|---|---|---|
| AKTS | — | — | — | — | — | — |
| ZBIO | $1.98B | -4.3 | 100.0% | -3777.4% | -156.8% | — |
| JBIO | $761M | -4.8 | — | — | -47.7% | — |
| MPLT | $773M | -0.9 | — | — | -151.1% | — |
| PURR | — | — | — | — | — | — |
| CDNA | $959M | -47.1 | 13.8% | -5.6% | -6.8% | — |
| CRVS | $575M | -14.5 | — | — | -21.6% | — |
| SVRA | $1.23B | -11.4 | — | — | -73.4% | — |
| MNKD | $1.75B | 283.5 | 22.2% | 1.7% | -11.1% | — |
Fundamental Lengkap Semua metrik per tahun — laporan laba rugi, neraca, arus kas
Neraca 18
| Metrik | Tren | 2025 |
|---|---|---|
| Cash & Equivalents | $38M | |
| Prepaid Expense | $4M | |
| Current Assets | $230M | |
| PP&E (Net) | $15M | |
| PP&E (Gross) | $20M | |
| Accum. Depreciation | $6M | |
| Total Assets | $265M | |
| Accounts Payable | $2M | |
| Accrued Liabilities | $10M | |
| Current Liabilities | $31M | |
| Capital Leases | $10M | |
| Total Liabilities | $78M | |
| Common Stock | $0 | |
| Retained Earnings | $-157M | |
| AOCI | $42.0K | |
| Stockholders' Equity | $-146M | |
| Liabilities + Equity | $265M | |
| Shares Outstanding | 915,261 |
Laporan Laba Rugi 13
| Metrik | Tren | Q1 2026 | Q1 2025 |
|---|---|---|---|
| Revenue | $3M | $1M | |
| R&D Expense | $20M | $16M | |
| SG&A Expense | $6M | $4M | |
| Operating Expenses | $26M | $20M | |
| Operating Income | $-23M | $-18M | |
| Interest Income | $4M | $3M | |
| Other Non-op | $-3.0K | $-13.0K | |
| Net Income | $-18M | $-15M | |
| EPS (Basic) | $-0.38 | $-18.60 | |
| EPS (Diluted) | $-0.38 | $-18.60 | |
| Shares (Basic) | 48,630,038 | 805,821 | |
| Shares (Diluted) | 48,630,038 | 805,821 | |
| EBITDA | $-22M | · |
Neraca 18
| Metrik | Tren | Q1 2026 | Q1 2025 |
|---|---|---|---|
| Cash & Equivalents | $372M | · | |
| Prepaid Expense | $5M | · | |
| Current Assets | $544M | · | |
| PP&E (Net) | $15M | · | |
| PP&E (Gross) | $21M | · | |
| Accum. Depreciation | $6M | · | |
| Total Assets | $577M | · | |
| Accounts Payable | $1M | · | |
| Accrued Liabilities | $6M | · | |
| Current Liabilities | $28M | · | |
| Capital Leases | $10M | · | |
| Total Liabilities | $71M | · | |
| Common Stock | $5.0K | · | |
| Retained Earnings | $-175M | · | |
| AOCI | $-241.0K | · | |
| Stockholders' Equity | $506M | · | |
| Liabilities + Equity | $577M | · | |
| Shares Outstanding | 53,403,173 | · |
Arus Kas 10
| Metrik | Tren | Q1 2026 | Q1 2025 |
|---|---|---|---|
| D&A | $652.0K | $484.0K | |
| Stock-based Comp | $3M | $1M | |
| Other Non-cash | $-10M | · | |
| Operating Cash Flow | $-24M | $-17M | |
| CapEx | $2M | $2M | |
| Investing Cash Flow | $21M | $39M | |
| Stock Issued | $5M | · | |
| Net Stock Activity | $5M | · | |
| Financing Cash Flow | $338M | $-468.0K | |
| Free Cash Flow | $-26M | · |
Profitabilitas 5
| Metrik | Tren | Q1 2026 | Q1 2025 |
|---|---|---|---|
| Operating Margin | -703.6% | · | |
| Net Margin | -567.9% | · | |
| EBITDA Margin | -683.4% | · | |
| ROA | -6.3% | · | |
| ROE | -7.2% | · |
Likuiditas & Solvabilitas 2
| Metrik | Tren | Q1 2026 | Q1 2025 |
|---|---|---|---|
| Current Ratio | 19.5 | · | |
| Quick Ratio | 13.3 | · |
Efisiensi 1
| Metrik | Tren | Q1 2026 | Q1 2025 |
|---|---|---|---|
| Asset Turnover | 0.0 | · |
Valuasi (TTM) 5
| Metrik | Tren | Q1 2026 | Q1 2025 |
|---|---|---|---|
| Market Cap | $955M | · | |
| P/B | 1.9 | · | |
| P / Tangible Book | 1.9 | · | |
| P / Cash Flow | -39.4 | · | |
| P / FCF | -36.6 | · |
Laporan Keuangan Laporan laba rugi, neraca, arus kas — tahunan, 5 tahun terakhir
Berita Terbaru Berita utama terbaru yang menyebutkan perusahaan ini
Metrik Saya Daftar pantauan pribadi Anda — baris yang dipilih dari Fundamental Lengkap
📊
Pilih metrik yang penting bagi Anda — klik ➕ di sebelah baris mana pun di Fundamental Lengkap di atas.
Pilihan Anda disimpan dan mengikuti Anda di semua ticker.